Full-Time

Associate Director/Director

Data Governance

Updated on 9/4/2026

Formation Bio

Formation Bio

51-200 employees

AI-driven platform accelerates clinical-stage drug development

Compensation Overview

$161.5k - $202k/yr

+ Equity

Boston, MA, USA + 1 more

More locations: New York, NY, USA

Hybrid

Hybrid schedule requires three days per week in the office. Applicants must reside in or be willing to relocate to the listed hiring areas.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
GMP
Machine Learning
Quality Assurance (QA)
Data Governance
Google Cloud Platform

Get referred to Formation Bio

See people who can refer or advise you

Requirements
  • The Associate Director level requires 7 or more years, or the Director level requires 10 or more years, of progressive GxP quality assurance, data integrity, or computerized systems compliance experience in a pharmaceutical, biotechnology, or related regulated industry.
  • A bachelor's degree in a scientific, engineering, information systems, or related discipline is required.
  • Strong working knowledge of data integrity principles, including ALCOA+, and applicable GMP, GCP, and/or GLP regulations as they pertain to data, records, and computerized systems is required.
  • Demonstrated experience with computer system assurance or validation, including risk-based approaches to initial context of use, changes in context of use, and functionality changes, is required.
  • Working knowledge of artificial intelligence and machine learning risk concepts, including model validation, bias, explainability, and drift monitoring, sufficient to design and approve AI risk assessments and mitigation strategies, is required.
  • Demonstrated experience building or maintaining data governance artifacts within an R&D setting, such as data inventories, data stewardship models, retention schedules, and access control frameworks, and overseeing AI applications used in R&D processes, is required.
  • Demonstrated experience serving as a Process Owner or System/Business Owner, including standard operating procedure governance, key performance indicator monitoring, and change control management, is required.
  • Experience leading or substantively contributing to cross-functional data migration, asset onboarding, or system change projects is required.
  • Experience representing Quality Assurance in working groups, inspections, or regulatory interactions is required.
  • The ability to operate independently and exercise sound judgment in a role reporting directly to the Head of Quality is required.
Responsibilities
  • Serve as Process Owner for R&D Data and Records Integrity and Business Owner for Veeva Quality Docs and DocuSign Part 11, ensuring these processes and systems remain accurate, current, and effective.
  • Own and maintain the R&D data governance framework, including the inventory of R&D data, categories, stewards and owners, source of truth, retention requirements, access controls, and associated risk assessments.
  • Apply risk assessments and control strategies to the initial context of use, changes in context of use, and functionality changes for computerized systems and AI tools.
  • Maintain the inventory of AI applications used across R&D and provide ongoing AI oversight, including periodic review of deployed models to assure continued control, compliance, and appropriate human accountability.
  • Serve as an R&D partner on data governance matters, advising R&D teams on data stewardship, data quality, and responsible AI adoption in daily R&D workflows.
  • Own and drive strategy for large cross-functional data migration and digitization projects, including asset onboarding or acquisition and system changes.
  • Establish guardrails, in partnership with Operational Excellence, for the use of AI in QMS process execution, including AI-assisted investigation drafting, CAPA analysis, and audit preparation.
  • Contribute to and support the QA master audit schedule and vendor qualification program, including evaluating vendors' use of AI or other automated systems in GxP-impacting work.
  • Oversee, review, and provide final approval for non-program-specific Quality Events, Investigations, and CAPAs.
  • Represent Quality Governance in regulatory inspections and third-party audits, and support inspection readiness activities.
  • Partner cross-functionally with R&D, IT, and Operational Excellence to embed Quality by Design principles into data, AI, and systems governance.

Formation Bio uses an AI-driven platform to speed up drug development by focusing on clinical-stage assets. It acquires and advances these assets using flexible financing structures, aiming to shorten timelines and cut costs for bringing new drugs to market. The core product is the proprietary AI tools that help with drug selection, development planning, and improving overall efficiency, enabling partnerships and successful commercialization with pharmaceutical and biotech companies. Compared with competitors, Formation Bio combines a data-powered approach with adaptable financing and asset acquisition strategies to move assets forward quickly and cost-effectively. The goal is to make treatments more accessible and affordable by accelerating development and enabling faster, more predictable commercialization through AI-enhanced decision making and flexible funding options.

Company Size

51-200

Company Stage

Series D

Total Funding

$530.3M

Headquarters

New York City, New York

Founded

2013

Get referred to Formation Bio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • January 29, 2026 Kenmare Bio in-licensed FHND5032, expanding autoimmune pipeline depth.
  • June 9, 2026 BLKR201 dosing created a near-term early-2027 catalyst.
  • Formation Bio raised $372 million in Series D, supporting pipeline and AI expansion.

What critics are saying

  • BLKR201 remains unproven; early-2027 readout determines whether Formation Bio justifies its model.
  • FHND5032 and BLKR201 concentrate value in two assets; one failure crushes leverage.
  • Without repeat clinical wins, Formation Bio becomes a costly AI wrapper around failed bets.

What makes Formation Bio unique

  • Formation Bio pairs AI software with clinical asset ownership, not pure-platform licensing.
  • July 22, 2026 hire Michael Ehlers strengthens translational and clinical development credibility.
  • June 9, 2026 BLKR201 entered Phase 1 five months after in-licensing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Jul 22nd, 2026
Formation Bio appoints Michael Ehlers as CSO to lead R&D strategy

Formation Bio has appointed Michael D. Ehlers as Chief Scientific Officer and Head of R&D. Ehlers will oversee portfolio strategy and advancement, from translational sciences through clinical development, and guide the scientific direction of Formation Bio's AI platform. Ehlers joins from MPM BioImpact, where he was an Entrepreneur Partner. He previously served as Executive Vice President of R&D at Biogen and held senior positions at Pfizer. Throughout his career, programmes under his leadership have produced six approved drugs spanning five indications and four drug modalities, with more than 40 programmes advanced into the clinic. Formation Bio is an AI-native pharma company that acquires clinical-stage assets and accelerates them through development using its proprietary AI platform.

PR Newswire
Jun 9th, 2025
Formation Bio Announces First Class Of Entrepreneurs In Residence To Drive Pipeline Growth And Strategic Partnerships

NEW YORK, June 9, 2025 /PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company focused on accelerating drug development, today announced the appointment of its first class of Entrepreneurs in Residence (EIRs): Kia Motesharei, Ph.D., Minji Kim Ph.D, MBA, John Taylor, M.S., and Anthony S. Walsh, D.Phil, These seasoned dealmakers will work closely with Chief Business Officer David Steinberg to expand the company's business development capabilities and further its mission to bring high-potential treatments to patients faster. Formation Bio acquires and in-licenses promising drug assets, advancing them through critical development milestones (Phase II and beyond), and then out-licensing for further advancement. The company's AI platform supports this lifecycle end-to-end—from asset identification and development strategy to execution of clinical trials aimed at greater speed and higher probability of success

Intelligence360 News
Jul 18th, 2024
Trialspark Dba Formation Bio Has Filed A Notice Of An Exempt Offering Of Securities To Raise $372,000,000.00 In New Equity Investment.

TrialSpark dba Formation Bio has filed a notice of an exempt offering of securities to raise $372,000,000.00 in New Equity Investment. TrialSpark dba Formation Bio has filed a notice of an exempt offering of securities to raise $372,000,000.00 in New Equity Investment.According to filings with the U.S. Securities and Exchange Commission, TrialSpark dba Formation Bio is raising up to $372,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Benjamine Liu played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.About TrialSpark dba Formation BioFormation Bio is a tech-driven pharmaceutical company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes critical aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data. The company acquires clinical-stage drugs from pharmaceutical and biotech companies with the goal to develop them faster in order to accelerate access to new treatments for patients, and to unlock greater value per program.To learn more about TrialSpark dba Formation Bio, visit http://www.formation.bio/TrialSpark dba Formation Bio Linkedin Page: https://www.linkedin.com/company/formationbio/Contact:Benjamine Liu, Chief Executive Officer866-283-7544https://www.linkedin.com/in/benjamine-liu-54306518/SOURCE: http://www.intelligence360.ioCopyright (c) 2024 SI360 Inc

FinSMEs
Jun 26th, 2024
Formation Bio Raises $372M in Series D Funding

Formation Bio, a NYC-based tech-driven and AI-native pharma company, raised $372M in Series D funding

HIT Consultant
May 21st, 2024
Sanofi, Formation Bio, Openai Partner On Ai-Powered Drug Discovery

What You Should Know:– Sanofi, a global pharmaceutical leader, Formation Bio, an AI-powered drug developer, and OpenAI, a leading research and development company in artificial intelligence, have announced a groundbreaking collaboration. The first-of-its-kind partnership in the pharma and life sciences industries aims to leverage AI to accelerate drug development and bring new medicines to patients faster.– Sanofi, Formation Bio, and OpenAI believe this collaboration will be a game-changer in the pharmaceutical industry. By combining their expertise in data, AI technology, and drug development, they aim to revolutionize the way new medicines are discovered and brought to market.A Symphony of ExpertiseThe collaboration will combine the unique strengths of each partner:Sanofi: Will contribute proprietary data for building custom AI models, furthering their goal of becoming the first biopharma company powered by AI at scale. This data will be crucial for training and refining the AI tools used in drug discovery.Will contribute proprietary data for building custom AI models, furthering their goal of becoming the first biopharma company powered by AI at scale. This data will be crucial for training and refining the AI tools used in drug discovery. OpenAI: World-renowned for its advancements in AI technology, OpenAI will contribute access to cutting-edge AI capabilities